Web Desc
Bile Acid Receptors as Signal Integrators in Liver and Metabolism
Organizer(s): Luciano Adorini, Kristina Schoonjans and Scott L. Friedman
Date: March 03 - 07, 2017
Location: Hyatt Regency Monterey, Monterey, CA, USA
Sponsored by Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Novo Nordisk A/S and Takeda Pharmaceutical Company Limited
Summary of Meeting:
In the last decade, bile acids have enjoyed a real renaissance, sparked by the identification at the turn of the millennium of their dedicated receptors, FXR and TGR5. This has been instrumental in revealing the key role bile acids play in regulating liver and metabolic homeostasis, transforming them from detergents facilitating the intestinal absorption of nutrients into versatile hormones. Signaling through FXR and TGR5 indeed modulates several metabolic pathways, regulating not only bile acid synthesis and enterohepatic recirculation, but also lipid, glucose and energy homeostasis. In addition, FXR and TGR5 agonists display anti-inflammatory and anti-fibrotic properties, making these agents interesting candidates for the treatment of several liver and metabolic diseases, including nonalcoholic steatohepatitis (NASH). With the hepatitis C virus infection nearly solved, NASH is already a medical problem of epidemic proportions poised to become by 2020 the leading indication for liver transplantation in the US. This conference will review genetics, structure and functions of bile acid receptors and will explore the intricate interactions among gut microbiota, bile acids and liver disease, as well as the multiple bidirectional signals along the gut-liver axis. Intriguingly, FXR agonists, like the bile acid derivative obeticholic acid, could have a beneficial role in the treatment of NASH by decreasing hepatic lipogenesis, steatosis and insulin resistance, while also inhibiting inflammatory and fibrogenic responses able to promote liver cirrhosis and hepatocellular carcinoma. The conference therefore aims at integrating basic, translational and clinical aspects of bile acid receptors, bringing together an interdisciplinary group of scientists to discuss the state of the art and propose new avenues of investigation in this active and dynamic field.
Scholarship Deadline: November 1 2016
Discounted Abstract Deadline: November 1 2016
Abstract Deadline: December 5 2016
Discounted Registration Deadline: January 9 2017
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Gilead Sciences, Inc.Intercept Pharmaceuticals, Inc.Novo Nordisk A/STakeda Pharmaceutical Company Limited
We gratefully acknowledge additional support for this conference from:
ALPCO
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Genmab A/S

Intercept Pharmaceuticals, Inc.
We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Grant No. 1R13DK112338-01
Funding for this conference was made possible (in part) by 1R13DK112338-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Friday, March 03 | 4:00PM - 8:00PM
Arrival and Registration
Room: Regency Foyer Terrace


Friday, March 03 | 6:00PM - 8:00PM
Welcome Mixer
Room: Regency Foyer Terrace
No registration fees are used to fund alcohol served at this function.

Saturday, March 04 | 7:30AM - 8:30AM
Breakfast
Room: Regency IV-VI


Saturday, March 04 | 8:00AM - 8:30AM
Poster Setup
Room: Regency IV-VI


Saturday, March 04 | 8:30AM - 5:00PM
Poster Viewing
Room: Regency IV-VI


Saturday, March 04 | 8:30AM - 9:30AM
Welcome and Keynote Address
Room: Regency Main I-III

Speaker 1 of 2
* Luciano Adorini, Intercept Pharmaceuticals, Inc., Italy

Saturday, March 04 | 8:30AM - 9:30AM
Welcome and Keynote Address
Room: Regency Main I-III

Speaker 2 of 2
Johan Auwerx, École Polytechnique Fédérale de Lausanne, Switzerland
New Insights into the Genetics of Mitochondria and Liver Metabolism

Saturday, March 04 | 9:30AM - 11:45AM
FXR and TGR5: Dedicated Bile Acid Sensors
Room: Regency Main I-III

Speaker 1 of 6
* Luciano Adorini, Intercept Pharmaceuticals, Inc., Italy

Saturday, March 04 | 9:30AM - 11:45AM
FXR and TGR5: Dedicated Bile Acid Sensors
Room: Regency Main I-III

Speaker 2 of 6
Kristina Schoonjans, École Polytechnique Fédérale de Lausanne – EPFL, Switzerland
TGR5 Signaling and Control of Metabolism

Saturday, March 04 | 9:30AM - 11:45AM
FXR and TGR5: Dedicated Bile Acid Sensors
Room: Regency Main I-III


Coffee Break

Saturday, March 04 | 9:30AM - 11:45AM
FXR and TGR5: Dedicated Bile Acid Sensors
Room: Regency Main I-III

Speaker 4 of 6
David J. Mangelsdorf, University of Texas Southwestern Medical Center, USA
Dissecting the Tissue-Specific Actions of Endocrine FGF Signaling

Saturday, March 04 | 9:30AM - 11:45AM
FXR and TGR5: Dedicated Bile Acid Sensors
Room: Regency Main I-III

Speaker 5 of 6
Ronald M. Evans, HHMI/The Salk Institute, USA
Gut Feelings: Control of Fatty Acid and Cholesterol Metabolism by Intestinal FXR

Saturday, March 04 | 9:30AM - 11:45AM
FXR and TGR5: Dedicated Bile Acid Sensors
Room: Regency Main I-III

Speaker 6 of 6
Saskia van Mil, UMC Utrecht, Netherlands
Short Talk: FXR as a Homeostat of Amino Acid Breakdown and Ureagenesis

Saturday, March 04 | 11:45AM - 12:45PM
Lunch
Room: Regency IV-VI


Saturday, March 04 | 12:00PM - 2:30PM
Poster Session 1
Room: Regency IV-VI


Saturday, March 04 | 2:30PM - 4:30PM
Workshop 1: Bile Acid Receptors in Health and Disease
Room: Regency Main I-III

Speaker 1 of 9
* Antonio Moschetta, Clinica Medica Frugoni, University of Bari, Italy

Saturday, March 04 | 2:30PM - 4:30PM
Workshop 1: Bile Acid Receptors in Health and Disease
Room: Regency Main I-III

Speaker 2 of 9
Jan Freark de Boer, University Medical Center Groningen, Netherlands
Intestinal FXR Controls Transintestinal Cholesterol Excretion in Mice

Saturday, March 04 | 2:30PM - 4:30PM
Workshop 1: Bile Acid Receptors in Health and Disease
Room: Regency Main I-III

Speaker 3 of 9
Hanns-Ulrich Marschall, Sahlgrenska Academy, University of Gothenburg, Sweden
Decreased Intestinal Glucose Absorption in Healthy Volunteers Treated with the FXR Agonist Obeticholic Acid

Saturday, March 04 | 2:30PM - 4:30PM
Workshop 1: Bile Acid Receptors in Health and Disease
Room: Regency Main I-III

Speaker 4 of 9
Richard Appleby, Imperial College, UK
A DIET1 Single Nucleotide Polymorphism (SNP) is Associated with Lower Fibroblast Growth Factor 19 (FGF19) and Serum Triglycerides (TG) in a Population of Non-Alcoholic Fatty Liver Disease (NAFLD)

Saturday, March 04 | 2:30PM - 4:30PM
Workshop 1: Bile Acid Receptors in Health and Disease
Room: Regency Main I-III

Speaker 5 of 9
Sayeepriyadarshini Anakk, University of Illinois at Urbana-Champaign, USA
Bile Acids - A Metabolite that Channels the Gender Gap in Hepatocellular Carcinoma

Saturday, March 04 | 2:30PM - 4:30PM
Workshop 1: Bile Acid Receptors in Health and Disease
Room: Regency Main I-III

Speaker 6 of 9
Raffaella M. Gadaleta, University of Bari, Italy
A Non-Tumorigenic FGF19 Analogue Protects Mice from Spontaneous Hepatocarcinogenesis

Saturday, March 04 | 2:30PM - 4:30PM
Workshop 1: Bile Acid Receptors in Health and Disease
Room: Regency Main I-III

Speaker 7 of 9
Mélanie Verreault, Laval University, Canada
FXR Agonists Inhibit Prostate Cancer Cell Proliferation Through AR-Dependent and –Independent Mechanisms

Saturday, March 04 | 2:30PM - 4:30PM
Workshop 1: Bile Acid Receptors in Health and Disease
Room: Regency Main I-III

Speaker 8 of 9
Karolina Emilia Zaborska, Cornell University, USA
TGR5 Contributes to Arterial Blood Pressure (AP) Lowering after Vertical Sleeve Gastrectomy in Mice

Saturday, March 04 | 2:30PM - 4:30PM
Workshop 1: Bile Acid Receptors in Health and Disease
Room: Regency Main I-III

Speaker 9 of 9
Moreshwar S. Desai, Baylor College of Medicine, USA
TGR5 Modulates Myocardial Adaptation to Stress

Saturday, March 04 | 4:30PM - 5:00PM
Coffee Available
Room: Regency Foyer Terrace


Saturday, March 04 | 5:00PM - 7:00PM
Genetics and Epigenetics of Bile Acid Receptors
Room: Regency Main I-III

Speaker 1 of 5
* Jelena Mann, Newcastle University, UK

Saturday, March 04 | 5:00PM - 7:00PM
Genetics and Epigenetics of Bile Acid Receptors
Room: Regency Main I-III

Speaker 2 of 5
David D. Moore, Baylor College of Medicine, USA
FXR Mutations Induce Cholestasis

Saturday, March 04 | 5:00PM - 7:00PM
Genetics and Epigenetics of Bile Acid Receptors
Room: Regency Main I-III

Speaker 3 of 5
Elizabeth K. Speliotes, University of Michigan, USA
Gene Set Enrichment Based on Human Genome-Wide Association Study Data Implicates FXR/RXR Activation as a Common Pathway Affecting Blood Lipids Levels and Nonalcoholic Fatty Liver Disease

Saturday, March 04 | 5:00PM - 7:00PM
Genetics and Epigenetics of Bile Acid Receptors
Room: Regency Main I-III

Speaker 4 of 5
Kim Jongsook Kemper, University of Illinois at Urbana-Champaign, USA
FGF15 Signal-Induced Phosphorylation of FXR in Bile Acid Regulation and Signal Termination

Saturday, March 04 | 5:00PM - 7:00PM
Genetics and Epigenetics of Bile Acid Receptors
Room: Regency Main I-III

Speaker 5 of 5
Andres Acosta, Mayo Clinic, USA
Short Talk: Obesity a State of Bile Acid Pathway Deficiency: Association of serum FGF-19, and GPBAR1 and NR1H4 Gene Variant with Gastrointestinal Traits, Body Weight and BMI in Obesity

Saturday, March 04 | 7:00PM - 7:00PM
On Own for Dinner


Sunday, March 05 | 7:30AM - 8:30AM
Breakfast
Room: Regency IV-VI


Sunday, March 05 | 8:30AM - 11:30AM
Interplay Between Bile Acids and the Gut Microbiome
Room: Regency Main I-III

Speaker 1 of 7
* Steven A. Kliewer, University of Texas Southwestern Medical Center, USA

Sunday, March 05 | 8:30AM - 11:30AM
Interplay Between Bile Acids and the Gut Microbiome
Room: Regency Main I-III

Speaker 2 of 7
Richard A. Flavell, HHMI/Yale University School of Medicine, USA
Role of the Intestinal Microbiome in Liver Disease

Sunday, March 05 | 8:30AM - 11:30AM
Interplay Between Bile Acids and the Gut Microbiome
Room: Regency Main I-III

Speaker 3 of 7
Fredrik Bäckhed, University of Gothenburg, Sweden
Functional Interactions between Gut Microbiota, Bile Acids and Host Metabolism

Sunday, March 05 | 8:30AM - 11:30AM
Interplay Between Bile Acids and the Gut Microbiome
Room: Regency Main I-III


Coffee Break

Sunday, March 05 | 8:30AM - 11:30AM
Interplay Between Bile Acids and the Gut Microbiome
Room: Regency Main I-III

Speaker 5 of 7
Frank J. Gonzalez, National Institutes of Health, USA
Gut Microbiota, Bile Acids, FXR and Metabolic Disease

Sunday, March 05 | 8:30AM - 11:30AM
Interplay Between Bile Acids and the Gut Microbiome
Room: Regency Main I-III

Speaker 6 of 7
Gary D. Wu, University of Pennsylvania, USA
Modulation of Gut Microbiota by the Bile Acid Derivative Obeticholic Acid

Sunday, March 05 | 8:30AM - 11:30AM
Interplay Between Bile Acids and the Gut Microbiome
Room: Regency Main I-III

Speaker 7 of 7
Sander Kersten, Wageningen University, Netherlands
Short Talk: Gut Microbiota Impacts Non-Alcoholic Fatty Liver Disease via Bile Acids

Sunday, March 05 | 11:30AM - 5:00PM
On Own for Lunch


Sunday, March 05 | 11:30AM - 1:00PM
Poster Setup
Room: Regency IV-VI


Sunday, March 05 | 1:00PM - 10:00PM
Poster Viewing
Room: Regency IV-VI


Sunday, March 05 | 4:30PM - 5:00PM
Coffee Available
Room: Regency Foyer Terrace


Sunday, March 05 | 5:00PM - 7:00PM
Gut-Liver Metabolic Axis
Room: Regency Main I-III

Speaker 1 of 5
* Kristina Schoonjans, École Polytechnique Fédérale de Lausanne – EPFL, Switzerland

Sunday, March 05 | 5:00PM - 7:00PM
Gut-Liver Metabolic Axis
Room: Regency Main I-III

Speaker 2 of 5
Frank Reimann, WellcomeTrust/MRC Institute of Metabolic Science & Metabolic Diseases Unit, UK
Molecular Mechanisms in Bile Acid-Stimulated GLP-1 Secretion

Sunday, March 05 | 5:00PM - 7:00PM
Gut-Liver Metabolic Axis
Room: Regency Main I-III

Speaker 3 of 5
Steven A. Kliewer, University of Texas Southwestern Medical Center, USA
Tissue-Specific Actions of Metabolic Hormones FGF15/19 and FGF21

Sunday, March 05 | 5:00PM - 7:00PM
Gut-Liver Metabolic Axis
Room: Regency Main I-III

Speaker 4 of 5
Antonio Moschetta, Clinica Medica Frugoni, University of Bari, Italy
Gut-Liver Axis in the Control of Cholestasis and HCC Development

Sunday, March 05 | 5:00PM - 7:00PM
Gut-Liver Metabolic Axis
Room: Regency Main I-III

Speaker 5 of 5
Catherine Williamson, King's College London, UK
Short Talk: Bile Acid Supplementation Alters the Gut Microbiome, Metabolome and Metagenome to Mimic the Intestinal Environment of Pregnancy

Sunday, March 05 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Regency IV-VI
No registration fees are used to fund alcohol served at this function.

Sunday, March 05 | 7:30PM - 10:00PM
Poster Session 2
Room: Regency IV-VI


Monday, March 06 | 7:30AM - 8:30AM
Breakfast
Room: Regency IV-VI


Monday, March 06 | 8:30AM - 11:30AM
Pathways to NASH, Liver Cirrhosis, and HCC
Room: Regency Main I-III

Speaker 1 of 7
* Michael Trauner, Medical University of Vienna, Austria

Monday, March 06 | 8:30AM - 11:30AM
Pathways to NASH, Liver Cirrhosis, and HCC
Room: Regency Main I-III

Speaker 2 of 7
Scott L. Friedman, Icahn School of Medicine at Mount Sinai, USA
Metabolic Dysregulation and Inflammation in the Pathogenesis of NASH, Hepatic Fibrosis and HCC


Monday, March 06 | 8:30AM - 11:30AM
Pathways to NASH, Liver Cirrhosis, and HCC
Room: Regency Main I-III

Speaker 3 of 7
Jelena Mann, Newcastle University, UK
Epigenetic Regulation in Liver Fibrosis

Monday, March 06 | 8:30AM - 11:30AM
Pathways to NASH, Liver Cirrhosis, and HCC
Room: Regency Main I-III


Coffee Break

Monday, March 06 | 8:30AM - 11:30AM
Pathways to NASH, Liver Cirrhosis, and HCC
Room: Regency Main I-III

Speaker 5 of 7
Li Wang, University of Connecticut, USA
Nuclear Receptor and lncRNA Crosstalk in Cholestatic Liver Injury

Monday, March 06 | 8:30AM - 11:30AM
Pathways to NASH, Liver Cirrhosis, and HCC
Room: Regency Main I-III

Speaker 6 of 7
Yujin Hoshida, UT Southwestern Medical Center, USA
Genetic and Genomic Features of Fatty Liver Disease, Fibrosis and Cancer

Monday, March 06 | 8:30AM - 11:30AM
Pathways to NASH, Liver Cirrhosis, and HCC
Room: Regency Main I-III

Speaker 7 of 7
Loning Fu, Baylor College of Medicine, USA
Short Talk: Circadian Dysfunction in Bile Acid Metabolism Promotes NAFLD-induced Hepatocarcinogenesis

Monday, March 06 | 11:30AM - 5:00PM
On Own for Lunch


Monday, March 06 | 11:30AM - 1:00PM
Poster Setup
Room: Regency IV-VI


Monday, March 06 | 1:00PM - 10:00PM
Poster Viewing
Room: Regency IV-VI


Monday, March 06 | 4:30PM - 5:00PM
Coffee Available
Room: Regency Foyer Terrace


Monday, March 06 | 5:00PM - 7:00PM
Metabolic Inflammation and NASH
Room: Regency Main I-III

Speaker 1 of 5
* David J. Mangelsdorf, University of Texas Southwestern Medical Center, USA

Monday, March 06 | 5:00PM - 7:00PM
Metabolic Inflammation and NASH
Room: Regency Main I-III

Speaker 2 of 5
Gökhan S. Hotamisligil, Harvard School of Public Health, USA
Immunometabolic Regulation of Liver Lipid Homeostasis

Monday, March 06 | 5:00PM - 7:00PM
Metabolic Inflammation and NASH
Room: Regency Main I-III

Speaker 3 of 5
Catherine Postic, INSERM Institut Cochin, France
Hepatokines in Metabolic Diseases: New Insights into FGF21 Regulation by Glucose

Monday, March 06 | 5:00PM - 7:00PM
Metabolic Inflammation and NASH
Room: Regency Main I-III

Speaker 4 of 5
Gyongyi Szabo, University of Massachusetts Medical School, USA
Immune Cell and Hepatocyte Cross-Talk in NASH

Monday, March 06 | 5:00PM - 7:00PM
Metabolic Inflammation and NASH
Room: Regency Main I-III

Speaker 5 of 5
Mark S. Sundrud, The Scripps Research Institute, USA
Short Talk: The Xenobiotic Transporter Mdr1 Permits T Cell Adaptation to Mucosa-Associated Bile Acids in the Ileum

Monday, March 06 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Regency IV-VI
No registration fees are used to fund alcohol served at this function.

Monday, March 06 | 7:30PM - 10:00PM
Poster Session 3
Room: Regency IV-VI


Tuesday, March 07 | 7:30AM - 8:30AM
Breakfast
Room: Regency IV-VI


Tuesday, March 07 | 8:30AM - 11:30AM
Targeting Bile Acid Receptors in Liver and Metabolic Disease
s

Room: Regency Main I-III

Speaker 1 of 7
* Scott L. Friedman, Icahn School of Medicine at Mount Sinai, USA

Tuesday, March 07 | 8:30AM - 11:30AM
Targeting Bile Acid Receptors in Liver and Metabolic Disease
s

Room: Regency Main I-III

Speaker 2 of 7
Michael Trauner, Medical University of Vienna, Austria
FXR Targeting in Cholestatic and Metabolic Liver Diseases

Tuesday, March 07 | 8:30AM - 11:30AM
Targeting Bile Acid Receptors in Liver and Metabolic Disease
s

Room: Regency Main I-III

Speaker 3 of 7
Verena Simone Keitel, University Hospital Duesseldorf, Germany
TGR5 in Liver Diseases

Tuesday, March 07 | 8:30AM - 11:30AM
Targeting Bile Acid Receptors in Liver and Metabolic Disease
s

Room: Regency Main I-III


Coffee Break

Tuesday, March 07 | 8:30AM - 11:30AM
Targeting Bile Acid Receptors in Liver and Metabolic Disease
s

Room: Regency Main I-III

Speaker 5 of 7
Bart Staels, Institut Pasteur de Lille, Université Lille, France
Nuclear Receptor Signaling in the Treatment of Liver and Metabolic Disorders

Tuesday, March 07 | 8:30AM - 11:30AM
Targeting Bile Acid Receptors in Liver and Metabolic Disease
s

Room: Regency Main I-III

Speaker 6 of 7
Luciano Adorini, Intercept Pharmaceuticals, Inc., Italy
Treatment of Liver and Metabolic Diseases by the FXR Agonist Obeticholic Acid: Preclinical Profile

Tuesday, March 07 | 8:30AM - 11:30AM
Targeting Bile Acid Receptors in Liver and Metabolic Disease
s

Room: Regency Main I-III

Speaker 7 of 7
Karim Christian El Kasmi, Boehringer Ingelheim Pharma, Germany
Short Talk: Intravenous FXR Agonist GW4064 Prevents Parenteral Nutrition Associated Cholestasis (PNAC) in Mice

Tuesday, March 07 | 11:30AM - 5:00PM
On Own for Lunch


Tuesday, March 07 | 2:30PM - 4:30PM
Workshop 2: Approaches to NASH Treatment
Room: Regency Main I-III

Speaker 1 of 8
* Bart Staels, Institut Pasteur de Lille, Université Lille, France

Tuesday, March 07 | 2:30PM - 4:30PM
Workshop 2: Approaches to NASH Treatment
Room: Regency Main I-III

Speaker 2 of 8
Pooja Jha, Nature Metabolism; Nature Research, Germany
Identification of Lipid Biomarkers of NAFLD using a Systems Genetics Approach


Tuesday, March 07 | 2:30PM - 4:30PM
Workshop 2: Approaches to NASH Treatment
Room: Regency Main I-III

Speaker 3 of 8
Barbara C. Hansen, University of South Florida, Tampa, USA
Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Nonhuman Primates (NHP’s) is Comparable to Humans for Metabolic Features, Histology and Imaging

Tuesday, March 07 | 2:30PM - 4:30PM
Workshop 2: Approaches to NASH Treatment
Room: Regency Main I-III

Speaker 4 of 8
Rui Eduardo Castro, Faculty of Pharmacy, University of Lisbon, Portugal
miR-21 Ablation and Obeticholic Acid Ameliorate NASH in Mice

Tuesday, March 07 | 2:30PM - 4:30PM
Workshop 2: Approaches to NASH Treatment
Room: Regency Main I-III

Speaker 5 of 8
Moshe Levi, Georgetown University, USA
The FXR/TGR5 Dual Agonist INT-767 Prevents and Reverses Western Diet-Induced NASH and Modulates Major Lipid Metabolic Pathways in Mic

Tuesday, March 07 | 2:30PM - 4:30PM
Workshop 2: Approaches to NASH Treatment
Room: Regency Main I-III

Speaker 6 of 8
Jonathan Roth, Intercept Pharmaceuticals, Inc., USA
Comparative Efficacy of INT-767 vs Liraglutide in Gubra AMLN Mice

Tuesday, March 07 | 2:30PM - 4:30PM
Workshop 2: Approaches to NASH Treatment
Room: Regency Main I-III

Speaker 7 of 8
Yusuke Sasaki, University of Tokyo, Japan
K-877 Prevents F4/80 Positive Cell Accumulation and Ballooning Degeneration in Non-Alcoholic Steatohepatitis (NASH) Model Mice

Tuesday, March 07 | 2:30PM - 4:30PM
Workshop 2: Approaches to NASH Treatment
Room: Regency Main I-III

Speaker 8 of 8
Andrew Billin, Gilead Sciences, USA
Pharmacodynamic Effects of the Oral, Non-Steroidal Farnesoid X Receptor Agonist Gs-9674 in Healthy Volunteers

Tuesday, March 07 | 4:30PM - 5:00PM
Coffee Available
Room: Regency Foyer Terrace


Tuesday, March 07 | 5:00PM - 7:00PM
NASH Therapeutics
Room: Regency Main I-III

Speaker 1 of 4
* Michael Trauner, Medical University of Vienna, Austria

Tuesday, March 07 | 5:00PM - 7:00PM
NASH Therapeutics
Room: Regency Main I-III

Speaker 2 of 4
Claus M. Kremoser, Phenex AG, Germany
Non-Steroidal FXR Agonists in the Treatment of NASH and Other Liver Diseases

Tuesday, March 07 | 5:00PM - 7:00PM
NASH Therapeutics
Room: Regency Main I-III

Speaker 3 of 4
David Shapiro, Intercept Pharmaceuticals, Inc., USA
Obeticholic Acid in the Treatment of NASH and Other Chronic Liver Diseases

Tuesday, March 07 | 5:00PM - 7:00PM
NASH Therapeutics
Room: Regency Main I-III

Speaker 4 of 4
Julian R.F. Walters, Imperial College London, UK
Short Talk: Beyond NASH and Liver Disease: Treatment of Bile Acid Diarrhea by Obeticholic Acid

Tuesday, March 07 | 7:00PM - 7:15PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Room: Regency Main I-III


Tuesday, March 07 | 7:15PM - 8:15PM
Social Hour with Lite Bites
Room: Regency IV-VI
No registration fees are used to fund alcohol served at this function.

Tuesday, March 07 | 8:00PM - 11:00PM
Entertainment
Room: Regency IV-VI
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources. Novo Nordisk A/S funding is not being used for this function.

Tuesday, March 07 | 8:00PM - 11:00PM
Cash Bar
Room: Regency IV-VI


Wednesday, March 08 | 10:25AM - 10:25AM
Departure


*Session Chair.